Eungu Kang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eungu Kang has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Young-Jun Rhie
Department of Pediatrics, Korea University College of Medicine, Seoul, Korea
16 shared publications - Hyo-Kyoung Nam
Department of Pediatrics, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
14 shared publications - Kee-Hyoung Lee
Department of Pediatrics, College of Medicine, Korea University, Seoul 02841, Republic of Korea
12 shared publications - Beom Hee Lee
Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
6 shared publications - Yu Jin Kim
Department of Pediatrics, Korea University College of Medicine, Seoul, Korea
6 shared publications - Kyeong Eun Oh
Department of Pediatrics, Woori Children’s Hospital, Seoul, Korea
5 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (24) , e169
Predictors of Treatment Outcomes in Pediatric Graves’ Disease
Shin DY, et al. J Korean Med Sci. 2026 Jun;41(24):e169. https://doi.org/10.3346/jkms.2026.41.e169
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (24) , e169
Open AccessPredictors of Treatment Outcomes in Pediatric Graves’ Disease
Shin DY, et al. J Korean Med Sci. 2026 Jun;41(24):e169. https://doi.org/10.3346/jkms.2026.41.e169
- Open Access
Non-HDL Cholesterol in Dyslipidemia Screening Among Korean Adolescents: A National Population-Based Survey
Background/Objectives: In pediatric lipid screening, non-high-density lipoprotein (non-HDL) cholesterol has gained relevance as a clinically feasible indicator that is increasingly applied. We assessed the population-level diagnostic performance and the influence of familial lipid risk in Korean adolescents. Methods: A nationally representative sample of 6989 adolescents aged 10–19 years (3684 boys and 3305 girls) was examined from the Korean National Health and Nutrition Examination Survey. We analyzed this nationally representative data to evaluate weighted and adjusted associations among non-HDL cholesterol level at or above 145 mg/dL, dyslipidemia, and parental lipid status. Results: The overall prevalence of dyslipidemia was 28.2% and 26.3% in Korean adolescent boys and girls, respectively. The prevalence of non-HDL cholesterol at or above 145 mg/dL was 7.2% and 9.2% in adolescent boys and girls, respectively. Elevated non-HDL cholesterol levels detected high directly measured or calculated low-density lipoprotein (LDL) cholesterol levels with a sensitivity of 72.9% and 54.0%, and a specificity of 99.7% and 99.8%, respectively, in adolescent boys, and a sensitivity of 77.5% and 64.8%, and a specificity of 99.5% and 99.2%, respectively, in adolescent girls. Compared with total cholesterol, non-HDL cholesterol more accurately identified adolescents with elevated LDL cholesterol in both sexes. These associations remained stable regardless of familial dyslipidemia history in adjusted weighted logistic regression models. Conclusions: Non-HDL cholesterol consistently distinguished adolescents with dyslipidemia independent of familial lipid status. Although a positive parental history increased the risk, non-HDL cholesterol remained a feasible pediatric screening tool in population-based evaluation.
Open AccessNon-HDL Cholesterol in Dyslipidemia Screening Among Korean Adolescents: A National Population-Based Survey
Background/Objectives: In pediatric lipid screening, non-high-density lipoprotein (non-HDL) cholesterol has gained relevance as a clinically feasible indicator that is increasingly applied. We assessed the population-level diagnostic performance and the influence of familial lipid risk in Korean adolescents. Methods: A nationally representative sample of 6989 adolescents aged 10–19 years (3684 boys and 3305 girls) was examined from the Korean National Health and Nutrition Examination Survey. We analyzed this nationally representative data to evaluate weighted and adjusted associations among non-HDL cholesterol level at or above 145 mg/dL, dyslipidemia, and parental lipid status. Results: The overall prevalence of dyslipidemia was 28.2% and 26.3% in Korean adolescent boys and girls, respectively. The prevalence of non-HDL cholesterol at or above 145 mg/dL was 7.2% and 9.2% in adolescent boys and girls, respectively. Elevated non-HDL cholesterol levels detected high directly measured or calculated low-density lipoprotein (LDL) cholesterol levels with a sensitivity of 72.9% and 54.0%, and a specificity of 99.7% and 99.8%, respectively, in adolescent boys, and a sensitivity of 77.5% and 64.8%, and a specificity of 99.5% and 99.2%, respectively, in adolescent girls. Compared with total cholesterol, non-HDL cholesterol more accurately identified adolescents with elevated LDL cholesterol in both sexes. These associations remained stable regardless of familial dyslipidemia history in adjusted weighted logistic regression models. Conclusions: Non-HDL cholesterol consistently distinguished adolescents with dyslipidemia independent of familial lipid status. Although a positive parental history increased the risk, non-HDL cholesterol remained a feasible pediatric screening tool in population-based evaluation.
- Open Access
Usefulness of Non-High-Density Lipoprotein Cholesterol for Screening Dyslipidemia in Children and Adolescents with Overweight or Obesity: A Single-Center Retrospective Study
Background/Objectives: Non-high-density lipoprotein (non-HDL) cholesterol provides a practical alternative for assessing dyslipidemia, with the advantage of not requiring fasting. The aim of this study was to evaluate the utility of non-HDL cholesterol measured in random (non-fasting) samples for screening dyslipidemia in children and adolescents with overweight or obesity. Methods: We retrospectively analyzed 751 children and adolescents (268 boys and 483 girls) aged 2 to 19 years with overweight or obesity. They underwent lipid profile evaluation without fasting. Dyslipidemia was defined as the presence of one or more of the following: total cholesterol ≥ 200 mg/dL, triglycerides ≥ 100 mg/dL (ages 0–9) or ≥130 mg/dL (ages 10–19), low-density lipoprotein (LDL) cholesterol ≥ 130 mg/dL, and HDL cholesterol < 40 mg/dL. A cutoff value of ≥145 mg/dL was used for non-HDL cholesterol. The sensitivity and specificity of non-HDL cholesterol were compared with those of fasting-state data from the Korean National Health and Nutrition Examination Survey. Results: Dyslipidemia was identified in 52.6% of children and adolescents with overweight or obesity. Non-HDL cholesterol ≥ 145 mg/dL was observed in 18.7% of boys and 17.0% of girls, and dyslipidemia was observed in 94.0% and 85.4% of boys and girls with high non-HDL cholesterol, respectively. Non-HDL cholesterol demonstrated excellent performance in detecting elevated measured LDL cholesterol, with a sensitivity and specificity of 100% and 92.0%, respectively, for boys and 97.8% and 91.3%, respectively, for girls. When stratified by age, non-HDL cholesterol showed sensitivity comparable to or higher than that of total cholesterol for both boys and girls. The sensitivity of non-HDL cholesterol in random samples was significantly higher than that of non-HDL cholesterol in fasting-state samples from boys (100% vs. 94.3%, p = 0.010), with a similar trend shown by girls (92.9% vs. 92.3%, p = 0.510). Conclusions: Non-HDL cholesterol measurement may be a reliable and practical tool for dyslipidemia screening in children and adolescents with overweight or obesity. Its applicability in non-fasting conditions makes it a convenient tool for routine clinical use.
Open AccessUsefulness of Non-High-Density Lipoprotein Cholesterol for Screening Dyslipidemia in Children and Adolescents with Overweight or Obesity: A Single-Center Retrospective Study
Background/Objectives: Non-high-density lipoprotein (non-HDL) cholesterol provides a practical alternative for assessing dyslipidemia, with the advantage of not requiring fasting. The aim of this study was to evaluate the utility of non-HDL cholesterol measured in random (non-fasting) samples for screening dyslipidemia in children and adolescents with overweight or obesity. Methods: We retrospectively analyzed 751 children and adolescents (268 boys and 483 girls) aged 2 to 19 years with overweight or obesity. They underwent lipid profile evaluation without fasting. Dyslipidemia was defined as the presence of one or more of the following: total cholesterol ≥ 200 mg/dL, triglycerides ≥ 100 mg/dL (ages 0–9) or ≥130 mg/dL (ages 10–19), low-density lipoprotein (LDL) cholesterol ≥ 130 mg/dL, and HDL cholesterol < 40 mg/dL. A cutoff value of ≥145 mg/dL was used for non-HDL cholesterol. The sensitivity and specificity of non-HDL cholesterol were compared with those of fasting-state data from the Korean National Health and Nutrition Examination Survey. Results: Dyslipidemia was identified in 52.6% of children and adolescents with overweight or obesity. Non-HDL cholesterol ≥ 145 mg/dL was observed in 18.7% of boys and 17.0% of girls, and dyslipidemia was observed in 94.0% and 85.4% of boys and girls with high non-HDL cholesterol, respectively. Non-HDL cholesterol demonstrated excellent performance in detecting elevated measured LDL cholesterol, with a sensitivity and specificity of 100% and 92.0%, respectively, for boys and 97.8% and 91.3%, respectively, for girls. When stratified by age, non-HDL cholesterol showed sensitivity comparable to or higher than that of total cholesterol for both boys and girls. The sensitivity of non-HDL cholesterol in random samples was significantly higher than that of non-HDL cholesterol in fasting-state samples from boys (100% vs. 94.3%, p = 0.010), with a similar trend shown by girls (92.9% vs. 92.3%, p = 0.510). Conclusions: Non-HDL cholesterol measurement may be a reliable and practical tool for dyslipidemia screening in children and adolescents with overweight or obesity. Its applicability in non-fasting conditions makes it a convenient tool for routine clinical use.
- Open Access
- 31 October 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (5) , 268-274
The role of continuous glucose monitoring in improving glycemic control in adolescents with type 1 diabetes
Purpose: Continuous glucose monitoring (CGM) technology offers real-time glucose feedback and has shown potential to improve glycemic control. This retrospective study evaluated the effect of CGM on glycemic outcomes in Korean children and adolescents with type 1 diabetes mellitus (T1DM) in a real-world setting.Methods: We included 66 participants divided into a CGM group (n=22) and a self-monitoring blood glucose (SMBG) group (n=44). We compared changes in hemoglobin A1c (HbA1c) of the 2 groups over 1 year and observed changes in CGM activation time, mean glucose, glucose management indicator (GMI), coefficient of variation (CV), time in range (TIR), and hypoglycemia.Results: The CGM group had a mean age of 16.63 years and time from diagnosis to the initiation of study of 4.19 years, while those of the SMBG group were 17.85 years and 5.19 years, respectively. In the CGM group, mean HbA1c decreased from 8.68% at baseline to 7.92% at 12 months (P=0.011), whereas HbA1c increased from 8.46% to 8.93% in the SMBG group (P<0.001). The changes in HbA1c at 1 year between the CGM and SMBG groups were significantly different (-0.76%±1.39% vs. 0.47%±1.38%, P=0.001). CGM activation time decreased slightly (89.09% to 79.24%, P=0.093), and there were no significant changes in TIR, mean glucose, GMI, CV, or hypoglycemia over time.Conclusion: CGM use in Korean children and adolescents with T1DM significantly improves HbA1c levels over 12 months compared to SMBG. The implementation of CGM may provide valuable benefits in glycemic control and potentially reduce the risk of diabetes-related complications.
- 31 October 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (5) , 268-274
Open AccessThe role of continuous glucose monitoring in improving glycemic control in adolescents with type 1 diabetes
Purpose: Continuous glucose monitoring (CGM) technology offers real-time glucose feedback and has shown potential to improve glycemic control. This retrospective study evaluated the effect of CGM on glycemic outcomes in Korean children and adolescents with type 1 diabetes mellitus (T1DM) in a real-world setting.Methods: We included 66 participants divided into a CGM group (n=22) and a self-monitoring blood glucose (SMBG) group (n=44). We compared changes in hemoglobin A1c (HbA1c) of the 2 groups over 1 year and observed changes in CGM activation time, mean glucose, glucose management indicator (GMI), coefficient of variation (CV), time in range (TIR), and hypoglycemia.Results: The CGM group had a mean age of 16.63 years and time from diagnosis to the initiation of study of 4.19 years, while those of the SMBG group were 17.85 years and 5.19 years, respectively. In the CGM group, mean HbA1c decreased from 8.68% at baseline to 7.92% at 12 months (P=0.011), whereas HbA1c increased from 8.46% to 8.93% in the SMBG group (P<0.001). The changes in HbA1c at 1 year between the CGM and SMBG groups were significantly different (-0.76%±1.39% vs. 0.47%±1.38%, P=0.001). CGM activation time decreased slightly (89.09% to 79.24%, P=0.093), and there were no significant changes in TIR, mean glucose, GMI, CV, or hypoglycemia over time.Conclusion: CGM use in Korean children and adolescents with T1DM significantly improves HbA1c levels over 12 months compared to SMBG. The implementation of CGM may provide valuable benefits in glycemic control and potentially reduce the risk of diabetes-related complications.
- Open Access
- 30 June 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (3) , 127-134
Predicting variables associated with diagnostic reevaluation of transient congenital hypothyroidism
Purpose: Current guidelines recommend immediate treatment after diagnosis of congenital hypothyroidism and reassessment of the hypothalamic-pituitary-thyroid axis at 3 years of age. As the known incidence of transient congenital hypothyroidism (TCH) has increased, experts have suggested the possibility of early drug discontinuation. Distinguishing TCH from permanent congenital hypothyroidism (PCH) is important to avoid prolonged treatment. We aimed to investigate the factors associated with TCH and to identify markers that indicate patients suitable for early treatment discontinuation.Methods: Participants were 167 children with congenital hypothyroidism. Subjects attempting to discontinue levothyroxine before 2 years of age were defined as the "early-off group." Cox proportional hazards models were used to identify factors associated with TCH and to determine factors predicting early drug discontinuation.Results: Totals of 96 (57%) and 71 children (43%) were classified as having TCH and PCH, respectively. In the Cox multivariate analysis, gestational age (GA) and low levothyroxine dose at 24 months of age were statistically associated with TCH. Based on receiver operating characteristic (ROC) curve analysis, an optimal cutoff dose for levothyroxine of 3.03 µg/kg/day at 18 months of age can predict early treatment discontinuation (P<0.001; sensitivity, 75.0%; specificity, 72.9%; area under the curve, 0.778).Conclusion: Our study showed that lower GA and lower levothyroxine doses during treatment were highly suggestive of TCH. Those requiring lower levothyroxine levels at 18 months of age could be candidates to cease medication prior to 3 years of age.
- 30 June 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (3) , 127-134
Open AccessPredicting variables associated with diagnostic reevaluation of transient congenital hypothyroidism
Purpose: Current guidelines recommend immediate treatment after diagnosis of congenital hypothyroidism and reassessment of the hypothalamic-pituitary-thyroid axis at 3 years of age. As the known incidence of transient congenital hypothyroidism (TCH) has increased, experts have suggested the possibility of early drug discontinuation. Distinguishing TCH from permanent congenital hypothyroidism (PCH) is important to avoid prolonged treatment. We aimed to investigate the factors associated with TCH and to identify markers that indicate patients suitable for early treatment discontinuation.Methods: Participants were 167 children with congenital hypothyroidism. Subjects attempting to discontinue levothyroxine before 2 years of age were defined as the "early-off group." Cox proportional hazards models were used to identify factors associated with TCH and to determine factors predicting early drug discontinuation.Results: Totals of 96 (57%) and 71 children (43%) were classified as having TCH and PCH, respectively. In the Cox multivariate analysis, gestational age (GA) and low levothyroxine dose at 24 months of age were statistically associated with TCH. Based on receiver operating characteristic (ROC) curve analysis, an optimal cutoff dose for levothyroxine of 3.03 µg/kg/day at 18 months of age can predict early treatment discontinuation (P<0.001; sensitivity, 75.0%; specificity, 72.9%; area under the curve, 0.778).Conclusion: Our study showed that lower GA and lower levothyroxine doses during treatment were highly suggestive of TCH. Those requiring lower levothyroxine levels at 18 months of age could be candidates to cease medication prior to 3 years of age.
- Open Access
- 13 June 2025
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 13 (6) , e70111
A Randomized, Double‐Blind, 2‐Treatment, 2‐Period, Crossover Phase 1 Study to Compare the Pharmacokinetics, Safety and Tolerability of 60 IU/Kg of Abcertin and Cerezyme in Healthy Volunteers Following a Single Intravenous Administration
Background: Imiglucerase (Cerezyme; Sanofi, Paris, France), an analogue of β‐glucocerebrosidase produced by recombinant DNA technology, has been a safe and effective treatment for Gaucher disease (GD) for over 25 years. A new imiglucerase, Abcertin (Seongnam‐si, Gyeonggi‐do, Republic of Korea) has shown a similar safety and efficacy profile in previous clinical studies. This study compared the pharmacokinetics, immunogenicity, safety, and tolerability to EU‐sourced Cerezyme following a single 60 IU/kg dose.Methods: This phase 1, single‐center, randomized, double‐blind, two‐way crossover study enrolled 36 healthy volunteers aged 18–45 years. Participants were randomly assigned to receive either Abcertin or Cerezyme in a predetermined sequence.Results: Abcertin reached peak plasma concentrations at a median tmax of 61 min (range: 40–121 min). The mean Cmax, AUC0–last, and AUC0–inf were 115.4 mU/mL, 12,190 min·mU/mL, and 12,210 min mU/mL, respectively, indicating bioequivalence to Cerezyme. The mean t½, CL, and Vz were 6.88 min, 376.7 mL/min, and 3.62 L, respectively, and were comparable between the two treatments. One participant in the Cerezyme group developed anti‐drug antibodies, which were non‐neutralizing A total of 24 subjects experienced treatment‐emergent adverse event (TEAE). The most common TEAE was headache (3 in the Abcertin group and 5 in the Cerezyme group), followed by general disorders and administration site condition (3 in Abcertin group and 5 in Cerezyme group). Two participants in the Cerezyme sequence experienced severe TEAEs: one had a urinary tract infection, and the other developed urticaria, which leading to study withdrawal.Conclusion: Abcertin demonstrated pharmacokinetic equivalence to Cerezyme, with a comparable safety, immunogenicity, and tolerability profile. These findings support its potential as an affordable biosimilar for GD treatment.
- 13 June 2025
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 13 (6) , e70111
Open AccessA Randomized, Double‐Blind, 2‐Treatment, 2‐Period, Crossover Phase 1 Study to Compare the Pharmacokinetics, Safety and Tolerability of 60 IU/Kg of Abcertin and Cerezyme in Healthy Volunteers Following a Single Intravenous Administration
Background: Imiglucerase (Cerezyme; Sanofi, Paris, France), an analogue of β‐glucocerebrosidase produced by recombinant DNA technology, has been a safe and effective treatment for Gaucher disease (GD) for over 25 years. A new imiglucerase, Abcertin (Seongnam‐si, Gyeonggi‐do, Republic of Korea) has shown a similar safety and efficacy profile in previous clinical studies. This study compared the pharmacokinetics, immunogenicity, safety, and tolerability to EU‐sourced Cerezyme following a single 60 IU/kg dose.Methods: This phase 1, single‐center, randomized, double‐blind, two‐way crossover study enrolled 36 healthy volunteers aged 18–45 years. Participants were randomly assigned to receive either Abcertin or Cerezyme in a predetermined sequence.Results: Abcertin reached peak plasma concentrations at a median tmax of 61 min (range: 40–121 min). The mean Cmax, AUC0–last, and AUC0–inf were 115.4 mU/mL, 12,190 min·mU/mL, and 12,210 min mU/mL, respectively, indicating bioequivalence to Cerezyme. The mean t½, CL, and Vz were 6.88 min, 376.7 mL/min, and 3.62 L, respectively, and were comparable between the two treatments. One participant in the Cerezyme group developed anti‐drug antibodies, which were non‐neutralizing A total of 24 subjects experienced treatment‐emergent adverse event (TEAE). The most common TEAE was headache (3 in the Abcertin group and 5 in the Cerezyme group), followed by general disorders and administration site condition (3 in Abcertin group and 5 in Cerezyme group). Two participants in the Cerezyme sequence experienced severe TEAEs: one had a urinary tract infection, and the other developed urticaria, which leading to study withdrawal.Conclusion: Abcertin demonstrated pharmacokinetic equivalence to Cerezyme, with a comparable safety, immunogenicity, and tolerability profile. These findings support its potential as an affordable biosimilar for GD treatment.
- Open Access
- 1 May 2025
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 68 (3) , 294-304
Constitutional Mismatch Repair Deficiency, the Most Aggressive Cancer Predisposition Syndrome : Clinical Presentation, Surveillance, and Management
Constitutional mismatch repair deficiency (CMMRD) is a rare and highly aggressive cancer predisposition syndrome caused by biallelic germline mutations in mismatch repair genes. This condition is characterized by early-onset malignancies across multiple organ systems, including central nervous system tumors, hematological cancers, and gastrointestinal malignancies. CMMRD-associated tumors exhibit hypermutation and microsatellite instability, resulting in a high tumor mutation burden and rendering these malignancies responsive to immune checkpoint inhibitors (ICIs). ICIs targeting programmed cell death protein-1 and programmed cell death ligand 1 have demonstrated remarkable efficacy, particularly in hypermutated tumors, providing durable responses and improving survival outcomes. Advances in genetic and molecular diagnostics have enhanced the ability to identify CMMRD early, allowing for the implementation of comprehensive surveillance programs and improved management strategies. A multidisciplinary and individualized approach is essential for managing CMMRD patients. This review underscores the importance of early diagnosis, surveillance, and emerging therapeutic approaches to improve outcomes and quality of life for individuals and families affected by this devastating syndrome.
- 1 May 2025
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 68 (3) , 294-304
Open AccessConstitutional Mismatch Repair Deficiency, the Most Aggressive Cancer Predisposition Syndrome : Clinical Presentation, Surveillance, and Management
Constitutional mismatch repair deficiency (CMMRD) is a rare and highly aggressive cancer predisposition syndrome caused by biallelic germline mutations in mismatch repair genes. This condition is characterized by early-onset malignancies across multiple organ systems, including central nervous system tumors, hematological cancers, and gastrointestinal malignancies. CMMRD-associated tumors exhibit hypermutation and microsatellite instability, resulting in a high tumor mutation burden and rendering these malignancies responsive to immune checkpoint inhibitors (ICIs). ICIs targeting programmed cell death protein-1 and programmed cell death ligand 1 have demonstrated remarkable efficacy, particularly in hypermutated tumors, providing durable responses and improving survival outcomes. Advances in genetic and molecular diagnostics have enhanced the ability to identify CMMRD early, allowing for the implementation of comprehensive surveillance programs and improved management strategies. A multidisciplinary and individualized approach is essential for managing CMMRD patients. This review underscores the importance of early diagnosis, surveillance, and emerging therapeutic approaches to improve outcomes and quality of life for individuals and families affected by this devastating syndrome.
- Open Access
- 28 February 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (1) , 31-37
Long-term outcomes of gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty
Purpose: This study aimed to examine the effects of gonadotropin-releasing hormone agonist (GnRHa) treatment on final height outcomes in girls with idiopathic central precocious puberty (CPP) from the start of treatment to their postmenarche visit.Methods: We conducted a retrospective analysis of 200 girls with idiopathic CPP who received GnRHa therapy, focusing on auxological and clinical outcomes at treatment initiation, treatment completion, and the last, postmenarche visit.Results: The mean chronological age (CA) at GnRHa treatment initiation was 8.24±0.73 years. The mean duration of GnRHa treatment was 3.12±0.81 years. The average age at menarche was 12.73±0.56 years, occurring a mean of 17.15±5.52 months after completing GnRHa therapy. The predicted adult height (PAH) standard deviation score (SDS) after menarche (0.48±0.99) was significantly greater than before treatment (-1.33±1.46) (P<0.001). Factors including greater bone age advancement (P<0.001), lower height SDS for CA at treatment initiation (P<0.001), and higher midparental height SDS (P=0.001) were positively associated with an increase in PAH SDS at the last visit. However, near-final height and the increase in PAH SDS at the last visit were not significantly different between patients who received early treatment (<8 years) and those who received later treatment (8–9 years).Conclusion: GnRHa treatment improved the final height outcomes in all girls with CPP, including those treated between 8 and 9 years of age.
- 28 February 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (1) , 31-37
Open AccessLong-term outcomes of gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty
Purpose: This study aimed to examine the effects of gonadotropin-releasing hormone agonist (GnRHa) treatment on final height outcomes in girls with idiopathic central precocious puberty (CPP) from the start of treatment to their postmenarche visit.Methods: We conducted a retrospective analysis of 200 girls with idiopathic CPP who received GnRHa therapy, focusing on auxological and clinical outcomes at treatment initiation, treatment completion, and the last, postmenarche visit.Results: The mean chronological age (CA) at GnRHa treatment initiation was 8.24±0.73 years. The mean duration of GnRHa treatment was 3.12±0.81 years. The average age at menarche was 12.73±0.56 years, occurring a mean of 17.15±5.52 months after completing GnRHa therapy. The predicted adult height (PAH) standard deviation score (SDS) after menarche (0.48±0.99) was significantly greater than before treatment (-1.33±1.46) (P<0.001). Factors including greater bone age advancement (P<0.001), lower height SDS for CA at treatment initiation (P<0.001), and higher midparental height SDS (P=0.001) were positively associated with an increase in PAH SDS at the last visit. However, near-final height and the increase in PAH SDS at the last visit were not significantly different between patients who received early treatment (<8 years) and those who received later treatment (8–9 years).Conclusion: GnRHa treatment improved the final height outcomes in all girls with CPP, including those treated between 8 and 9 years of age.
- Open Access
- 31 December 2024
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 29 (6) , 349-355
Cohort profile: Multicenter Networks for Ideal Outcomes of Rare Pediatric Endocrine and Metabolic Diseases in Korea (OUTSPREAD study)
Rare endocrine diseases are complex conditions that require lifelong specialized care due to their chronic nature and associated long-term complications. In Korea, a lack of nationwide data on clinical practice and outcomes has limited progress in patient care. Therefore, the Multicenter Networks for Ideal Outcomes of Pediatric Rare Endocrine and Metabolic Disease (OUTSPREAD) study was initiated. This study involves 30 centers across Korea. The study aims to improve the long-term prognosis of Korean patients with rare endocrine diseases by collecting comprehensive clinical data, biospecimens, and patient-reported outcomes to identify complications and unmet needs in patient care. Patients with childhood-onset pituitary, adrenal, or gonadal disorders, such as craniopharyngioma, congenital adrenal hyperplasia (CAH), and Turner syndrome were prioritized. The planned enrollment is 1,300 patients during the first study phase (2022–2024). Clinical, biochemical, and imaging data from diagnosis, treatment, and follow-up during 1980–2023 were retrospectively reviewed. For patients who agreed to participate in the prospective cohort, clinical data and biospecimens will be prospectively collected to discover ideal biomarkers that predict the effectiveness of disease control measures and prognosis. Patient-reported outcomes, including quality of life and depression scales, will be evaluated to assess psychosocial outcomes. Additionally, a substudy on CAH patients will develop a steroid hormone profiling method using liquid chromatography-tandem mass spectrometry to improve diagnosis and monitoring of treatment outcomes. This study will address unmet clinical needs by discovering ideal biomarkers, introducing evidence-based treatment guidelines, and ultimately improving long-term outcomes in the areas of rare endocrine and metabolic diseases.
- 31 December 2024
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 29 (6) , 349-355
Open AccessCohort profile: Multicenter Networks for Ideal Outcomes of Rare Pediatric Endocrine and Metabolic Diseases in Korea (OUTSPREAD study)
Rare endocrine diseases are complex conditions that require lifelong specialized care due to their chronic nature and associated long-term complications. In Korea, a lack of nationwide data on clinical practice and outcomes has limited progress in patient care. Therefore, the Multicenter Networks for Ideal Outcomes of Pediatric Rare Endocrine and Metabolic Disease (OUTSPREAD) study was initiated. This study involves 30 centers across Korea. The study aims to improve the long-term prognosis of Korean patients with rare endocrine diseases by collecting comprehensive clinical data, biospecimens, and patient-reported outcomes to identify complications and unmet needs in patient care. Patients with childhood-onset pituitary, adrenal, or gonadal disorders, such as craniopharyngioma, congenital adrenal hyperplasia (CAH), and Turner syndrome were prioritized. The planned enrollment is 1,300 patients during the first study phase (2022–2024). Clinical, biochemical, and imaging data from diagnosis, treatment, and follow-up during 1980–2023 were retrospectively reviewed. For patients who agreed to participate in the prospective cohort, clinical data and biospecimens will be prospectively collected to discover ideal biomarkers that predict the effectiveness of disease control measures and prognosis. Patient-reported outcomes, including quality of life and depression scales, will be evaluated to assess psychosocial outcomes. Additionally, a substudy on CAH patients will develop a steroid hormone profiling method using liquid chromatography-tandem mass spectrometry to improve diagnosis and monitoring of treatment outcomes. This study will address unmet clinical needs by discovering ideal biomarkers, introducing evidence-based treatment guidelines, and ultimately improving long-term outcomes in the areas of rare endocrine and metabolic diseases.
- Open Access
- 30 June 2024
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 29 (3) , 161-166
Long-term efficacy of a triptorelin 3-month depot in girls with central precocious puberty
Purpose: Three-month gonadotropin-releasing hormone agonists (GnRHas) are expected to achieve better compliance in patients with central precocious puberty (CPP) compared to the monthly formulation. However, 1-month depot remains the dominant choice for conventional treatment worldwide. Our study aimed to investigate the long-term efficacy of a 3-month GnRHa for CPP treatment.Methods: In this retrospective study, 69 Korean girls with CPP were prescribed either triptorelin pamoate (TP) 3-month depot (n=29) or triptorelin acetate (TA) 1-month depot (n=40) and were followed for 1 year after the end of treatment. Auxological, radiological, and biochemical data were collected every 6 months.Results: Baseline characteristics were similar between the 2 groups. In the TP 3-month depot group, 27 of 29 patients (93.1%) exhibited suppressed luteinizing hormone level (below 2.5 IU/L) after 6 months of treatment, and this suppression level was reserved until the final injection. The degree of bone age advancement in the TP 3-month depot group decreased from 1.8±0.4 years at the start of treatment to 0.6±0.5 years at 1-year posttreatment. The gain in predicted adult height (PAH) 1 year after the end of treatment was similar between the TP 3-month and TA 1-month depot groups (5.2±3.1 and 5.3±2.4 cm, respectively; p=0.875).Conclusion: A 3-month depot of triptorelin effectively inhibited gonadal and sex hormones, suppressed bone maturation, and increased PAH. For patient convenience, we suggest a 3-month GnRHa regimen as a promising CPP treatment option.
- 30 June 2024
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 29 (3) , 161-166
Open AccessLong-term efficacy of a triptorelin 3-month depot in girls with central precocious puberty
Purpose: Three-month gonadotropin-releasing hormone agonists (GnRHas) are expected to achieve better compliance in patients with central precocious puberty (CPP) compared to the monthly formulation. However, 1-month depot remains the dominant choice for conventional treatment worldwide. Our study aimed to investigate the long-term efficacy of a 3-month GnRHa for CPP treatment.Methods: In this retrospective study, 69 Korean girls with CPP were prescribed either triptorelin pamoate (TP) 3-month depot (n=29) or triptorelin acetate (TA) 1-month depot (n=40) and were followed for 1 year after the end of treatment. Auxological, radiological, and biochemical data were collected every 6 months.Results: Baseline characteristics were similar between the 2 groups. In the TP 3-month depot group, 27 of 29 patients (93.1%) exhibited suppressed luteinizing hormone level (below 2.5 IU/L) after 6 months of treatment, and this suppression level was reserved until the final injection. The degree of bone age advancement in the TP 3-month depot group decreased from 1.8±0.4 years at the start of treatment to 0.6±0.5 years at 1-year posttreatment. The gain in predicted adult height (PAH) 1 year after the end of treatment was similar between the TP 3-month and TA 1-month depot groups (5.2±3.1 and 5.3±2.4 cm, respectively; p=0.875).Conclusion: A 3-month depot of triptorelin effectively inhibited gonadal and sex hormones, suppressed bone maturation, and increased PAH. For patient convenience, we suggest a 3-month GnRHa regimen as a promising CPP treatment option.